An NDA-stage biologics-development programme is being structured around CHO-MK cell-line development, stable pools, clone screening, cell banking and fed-batch process readiness.
Imperion Biotechnology is structuring an NDA-stage biologics-development programme with a confidential pharmaceutical partner.
The proposed programme is designed to establish a scalable CHO-MK cell-line and process-development library for future biosimilar and recombinant-protein programmes.
The planned pilot will assess cell-line access and adaptation, vector and gene-of-interest strategy, stable-pool generation, clone screening, lead-clone selection, cell banking and mini fed-batch process development.